Novel ALK inhibitors in clinical use and development

Chaitanya Iragavarapu; Milaim Mustafa; Akintunde Akinleye; Muhammad Furqan; Varun Mittal; Shundong Cang; Delong Liu

doi:10.1186/s13045-015-0122-8

Back

Novel ALK inhibitors in clinical use and development

Journal article

Open access

Peer reviewed

Novel ALK inhibitors in clinical use and development

Chaitanya Iragavarapu, Milaim Mustafa, Akintunde Akinleye, Muhammad Furqan, Varun Mittal, Shundong Cang and Delong Liu

Journal of hematology and oncology, Vol.8(1), pp.17-17

02/27/2015

DOI: 10.1186/s13045-015-0122-8

PMCID: PMC4349797

PMID: 25888090

Files and links (1)

url

https://doi.org/10.1186/s13045-015-0122-8View

Published (Version of record) Open Access

Abstract

Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. ALK-1 was initially found in anaplastic large cell lymphoma (ALCL). ALK mutations have also been implicated in the pathogenesis of non-small cell lung cancer (NSCLC) and other solid tumors. Multiple small molecule inhibitors with activity against ALK and related oncoproteins are under clinical development. Two of them, crizotinib and ceritinib, have been approved by FDA for treatment of locally advanced and metastatic NSCLC. More agents (alectinib, ASP3026, X396) with improved safety, selectivity, and potency are in the pipeline. Dual inhibitors targeting ALK and EGFRm (AP26113), TRK (TSR011), FAK (CEP-37440), or ROS1 (RXDX-101, PF-06463922) are under active clinical development.

Receptor Protein-Tyrosine Kinases - antagonists & inhibitors

Antineoplastic Agents - pharmacology

Protein Kinase Inhibitors - pharmacology

Animals

Humans

Neoplasms - drug therapy

Details

Title: Subtitle: Novel ALK inhibitors in clinical use and development
Creators: Chaitanya Iragavarapu - Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA. Iragavarapuc@wcmc.com
Milaim Mustafa - Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA. mmustafa@une.edu
Akintunde Akinleye - Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, 10595, USA. docakin@gmail.com
Muhammad Furqan - Department of Medicine, Division of Hematology and Oncology, University of Iowa Carver College of Medicine, Iowa City, IA, 52242, USA. dr_furqandow@yahoo.com
Varun Mittal - Department of Medicine, Division of Hematology/Oncology, Albert Einstein Medical Center, Philadelphia, PA, 19141, USA. varun.doc7@gmail.com
Shundong Cang - Department of Oncology, Henan Province People's Hospital|, Zhengzhou University, Zhengzhou, China. cangshundong@163.com
Delong Liu - Henan Cancer Hospital, Zhengzhou University, Zhengzhou, China. delong_liu@nymc.edu
Resource Type: Journal article
Publication Details: Journal of hematology and oncology, Vol.8(1), pp.17-17
DOI: 10.1186/s13045-015-0122-8
PMID: 25888090
PMCID: PMC4349797
NLM abbreviation: J Hematol Oncol
ISSN: 1756-8722
eISSN: 1756-8722
Language: English
Date published: 02/27/2015
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984094330102771

Metrics

25 Record Views

87 Times Cited - Web of Science